Monitor for future Form 4 filings by the new CCO for any open-market purchases or sales, which could signal insider conviction. No immediate trading catalyst.
TARS drugs
TARS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $68.60entry
- T+1 · 8d ago +3.27%α +0.90% · $70.84
- T+5 · 4d ago +17.03%α +14.43% · $80.28
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neera Clase, the new Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership, disclosing 14,800 shares of common stock, options to purchase 76,861 shares at various exercise prices, and 12,105 restricted stock units. This is a routine filing required upon becoming an officer and provides no new financial or strategic information.
Key Facts
- Neera Clase appointed Chief Commercial Officer of Tarsus Pharmaceuticals, Inc.
- Filed Form 3 on 2026-11-05, reporting 14,800 shares of common stock owned directly.
- Holds options to purchase 23,000 shares at $25.56, 18,701 at $19.59, 14,909 at $15.00, 9,119 at $35.50, 6,126 at $44.54, and 5,007 at $74.90.
- Holds 2,864, 3,080, 3,014, and 3,147 restricted stock units (RSUs) with various vesting schedules starting March 15, 2027.
- No transactions or changes in company operations reported.
Financial Impact
No financial impact; routine insider ownership disclosure.
Risk Factors
- None identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0002162845-26-000004 |
| Document: 0002162845-26-000004-index-headers.html | 0002162845-26-000004 |
| Document: 0002162845-26-000004-index.html | 0002162845-26-000004 |
| Document: 0002162845-26-000004.txt | 0002162845-26-000004 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Viewing Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers